Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 37

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 37
---
statement of annual or interim financial statements will not be prevented or detected on a timely basis.
Section 404 of the Sarbanes-Oxley Act also generally requires an attestation from our independent registered public accounting firm on
the effectiveness of our internal control over financial reporting. However, for as long as we remain a non-accelerated filer, we are
not required to comply with the independent registered public accounting firm attestation requirement.

In previous years, we and
our independent registered public accounting firm have identified material weaknesses in our internal controls over financial reporting.
Although we have instituted remedial measures to address the material weaknesses identified and to continually review and evaluate our
internal control systems to allow management to report on the sufficiency of our internal control over financial reporting, we cannot
assure you that we will not discover additional weaknesses in our internal control over financial reporting. Any such additional weaknesses
or failure to adequately remediate any existing weakness could materially and adversely affect our financial condition and results of
operations, as well as our ability to accurately report our financial condition and results of operations in a timely and reliable
manner.

Additionally, the material
weaknesses previously identified, or other material weaknesses or significant deficiencies we may become aware of in the future, could
result in our determining that our controls and procedures are not effective in future periods or could result in a material misstatement
of the consolidated financial statements that would not be prevented or detected.

Any failure to maintain effective
internal controls over financial reporting could severely inhibit our ability to accurately report our financial condition, results of
operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent
registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial
reporting once that firm begin its Section 404 reviews, we could lose investor confidence in the accuracy and completeness of our financial
statements and reports, the market price of our Ordinary Shares and/or Depositary Shares could decline, and we could be subject to sanctions
or investigations by NASDAQ, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control
over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict
our future access to the capital markets.

Risks Related to Our Business, Strategy and Industry

We have undertaken in the past, and may in the future undertake, strategic acquisitions. Failure to integrate acquisitions could adversely affect our value.